Association of plasma pentosidine concentrations with renal function in kidney graft recipients

Clinical Transplantation

Volumn 24, Issue 6, 2010, Pages 839-847

  Slowik Zylka, Dorota ^a   Safranow, Krzysztof ^a   Dziedziejko, Violetta ^a   Ciechanowski, Kazimierz ^a   Chlubek, Dariusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Creatinine clearance; Diuresis; High performance liquid chromatography; Kidney transplantation; Pentosidine

Indexed keywords

CREATININE; PENTOSIDINE; UREA;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DIURESIS; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; MATHEMATICAL MODEL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME; URINE VOLUME;

ARGININE; CROSS-LINKING REAGENTS; DIABETES MELLITUS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LYSINE; MALE; MIDDLE AGED; PROGNOSIS;

EID: 78649978054     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01176.x     Document Type: Article

References (33)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994: 70: 138.
2. Smith MA, Taneda S, Richey PL et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994: 91: 5710.
3. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984: 101: 527.
4. Henle T, Deppisch R, Beck W, Hergesell O, Hänsch GM, Ritz E. Advanced glycated end-products (AGE) during hemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999: 14: 1968.
5. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994: 343: 1519.
6. Hartog JW, Smit AJ, Van Son WJ et al. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 2004: 43: 966.
7. Waanders F, Van Den Berg E, Nagai R, Van Veen I, Navis G, Van Goor H. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats. Nephrol Dial Transplant 2008: 23: 518.
8. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 1989: 264: 21597.
9. Sell D, Monnier V. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990: 85: 380.
10. Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997: 51: 1170.
11. Miyata T, Ueda Y, Horie K et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 1998: 53: 416.
12. Miyata T, Ueda Y, Shinzato T et al. Acumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996: 7: 1198.
13. Slowik-Zylka D, Safranow K, Dziedziejko V, Bukowska H, Ciechanowski K, Chlubek D. A sensitive and specific HPLC method for the determination of total pentosidine concentration in plasma. J Biochem Biophys Methods 2004: 61: 313.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976: 72: 248.
15. Slowik-Zylka D, Safranow K, Dziedziejko V, Dutkiewicz G, Ciechanowski K, Chlubek D. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients. J Nephrol 2006: 19: 65.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002: 39: 1.
17. Harzallah K, Sellam A, Mhiri A et al. Creatinine clearance estimation after kidney transplantation: an analysis of three methods. Transplant Proc 2007: 39: 2571.
18. White CA, Huang D, Akbari A, Garland J, Knoll GA. Performance of creatinine-based estimates of GFR in kidney transplant recipients: a systematic review. Am J Kidney Dis 2008: 51: 1005.
19. Miyata T, Van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999: 55: 389.
20. Hricik DE, Schulak AJ, Sell D, Fogarty JF, Monnier V. Effects of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993: 43: 398.
21. Miyata T, Ueda Y, Yoshida A et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997: 51: 880.
22. Antolini F, Valente F, Ricciardi D, Baroni M, Fagugli RM. Principal component analysis of some oxidative stress parameters and their relationships in hemodialytic and transplanted patients. Clin Chim Acta 2005: 358: 87.
23. Kato H, Van Chuyen N, Shinoda T, Sekiya F, Hayase F. Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta 1990: 1035: 71.
24. Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl 1999: 731: 23.
25. Yoshida K, Yoneda T, Fujimoto K, Hirao Y, Konishi N. Pentosidine and its deposition in renal tissue in renal transplantation. Transplant Proc 2005: 37: 4266.
26. Stein G, Franke S, Mahiout A et al. Influence of dialysis modalities on serum AGEs levels in end-stage renal disease patients. Nephrol Dial Transplant 2001: 16: 999.
27. Stein G, Franke S, Sperschneider H et al. Decrease in serum pentosidine levels of ESRD patients during polysulfone hemodialysis. Nephrol Dial Transplant 1999: 14: 1606.
28. Antolini F, Valente F, Ricciardi D, Fagugli RM. Normalization of oxidative stress parameters after kidney transplant is secondary to full recovery of renal function. Clin Nephrol 2004: 62: 131.
29. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994: 91: 11704.
30. Jadoul M, Ueda Y, Yasuda Y et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of carbonyl stress. Kidney Int 1999: 55: 2487.
31. Franke S, Müller A, Sommer M, Busch M, Kientsch-Engel R, Stein G. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 2003: 59: 88.
32. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999: 257: 251.
33. Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans 2007: 35: 853.